Published
08/17/2025, 17:49At a meeting of the Eurasian Intergovernmental Council, a concept for the development of a common market for medicines within the Eurasian Economic Union was approved.
The document aims to ensure the sustainable functioning of this market based on mandatory requirements for the safety, efficacy and quality of medicines.
The concept provides a brief overview of the current state of the pharmaceutical market in the EAEU.
It was noted that it actually started in 2019, when the registration of medicines under the rules of the union began and, within the framework of the integrated information system of the EAEU, common processes were put in place to ensure information exchange between authorised bodies in the field of registration, examination and inspection for compliance with the union's GMP rules.
The concept identifies the main areas for further market development as improving and optimising registration procedures and the regulation of medicines, increasing the efficiency of information systems, developing infrastructure and competencies in the union countries, their cooperation in the production of pharmaceutical products, and regulating the circulation of medicines, taking into account international experience.
Registration certificates for medicinal products issued under national rules will remain valid until 2026. In order to continue to be marketed in the customs territory of the EAEU, such medicinal products must undergo a procedure to bring their registration dossiers into line with the union's acts and be included in the EAEU's Unified Register of Registered Medicinal Products.
From 1 January 2026, only medicinal products with EAEU registration certificates will be accepted in the member states.
The implementation of the document adopted by the Intergovernmental Council should ultimately improve the availability of safe and high-quality medicines for citizens of the union countries.
